Figure 1.
Avadomide effects on immune activation in peripheral blood. (A) Aiolos expression in peripheral CD19+ B and CD3+ T cells. (B) Ex vivo IFN-γ production in response to anti-CD3 stimulation. (C) Total peripheral blood CD8+ T cells and shifts in CD8+ T-cell subsets (naive, activated, memory). (D) TCR-β expression levels (log10-transformed number of CDR3 reads) at baseline vs on-treatment are plotted. Color indicates a significant differential expression (red, not significant; blue, significant; adjusted P < .001) or publicly identified TCR sequence with known antigen (green). Changes in TCR-β productive clonality and richness from baseline to end of cycle 2 are shown for each patient. Extent of change in percentage of baseline (0 indicating no change) is plotted.